MarketCap
Facebook
X
TelegramGeschäftsbericht 2022
hinzugefügt 21.12.2024
IMV Betriebsaufwand 2011-2026 | IMV
Betriebsaufwand Jährlich IMV
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 35.1 M | 26.7 M | 21 M | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 35.1 M | 21 M | 27.6 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aquestive Therapeutics
AQST
|
85.5 M | $ 4.14 | 0.36 % | $ 443 M |  USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
158 M | $ 8.41 | 4.73 % | $ 230 M |  Israel |
 |
Ardelyx
ARDX
|
95.9 M | $ 6.06 | 1.94 % | $ 1.46 B | USA |
 |
argenx SE
ARGX
|
3.19 B | $ 752.35 | 0.79 % | $ 25 B |  Niderland |
 |
Arcutis Biotherapeutics
ARQT
|
137 M | $ 23.83 | 0.85 % | $ 3.03 B | USA |
 |
Aytu BioScience
AYTU
|
53.7 M | $ 2.65 | -1.12 % | $ 16.6 M | USA |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B |  France |
 |
BioCardia
BCDA
|
15.7 M | $ 1.2 | -0.04 % | $ 8 M | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
144 M | $ 9.6 | 6.37 % | $ 1.98 B | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
1.07 B | $ 9.48 | -3.27 % | $ 613 M | USA |
 |
BioVie
BIVI
|
18.1 M | $ 1.45 | 2.09 % | $ 2.14 M | USA |
 |
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | USA |
 |
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
BioLineRx Ltd.
BLRX
|
28.1 M | $ 2.32 | 4.98 % | $ 908 M | Israel |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
BioMarin Pharmaceutical
BMRN
|
1.47 B | $ 56.49 | 1.78 % | $ 10.8 B | USA |
 |
BioNTech SE
BNTX
|
512 M | $ 92.3 | 1.23 % | $ 27.2 B | Germany |
 |
Allena Pharmaceuticals
ALNA
|
47.6 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
50.6 M | - | 10.36 % | $ 9.8 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
51.4 M | $ 3.04 | 1.54 % | $ 259 M | USA |
 |
BioXcel Therapeutics
BTAI
|
107 M | $ 1.16 | -2.12 % | $ 14.2 M | USA |
 |
Burford Capital Limited
BUR
|
106 M | $ 4.54 | 9.54 % | $ 683 M | Britain |
 |
Cabaletta Bio
CABA
|
172 M | $ 3.2 | 7.94 % | $ 322 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 3.21 | 4.56 % | $ 6.98 B | Israel |
 |
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | USA |
 |
Catalyst Biosciences
CBIO
|
105 M | $ 19.97 | 2.94 % | $ 1.78 B | USA |
 |
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Codexis
CDXS
|
31.5 M | $ 1.97 | 7.97 % | $ 172 M | USA |
 |
Cerus Corporation
CERS
|
149 M | $ 1.91 | 2.42 % | $ 364 M | USA |
 |
Cullinan Management
CGEM
|
242 M | $ 15.4 | 6.72 % | $ 928 M | USA |
 |
Coherus BioSciences
CHRS
|
231 M | $ 1.75 | 0.87 % | $ 205 M | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |
 |
AstraZeneca PLC
AZN
|
17.6 B | - | - | $ 96.9 B | Britain |